

**BTG** BTG

Imagine where we can go.

Ian Harvey appointed chairman of Intellectual Property Institute

28 September 1999

Ian Harvey, chief executive of BTG plc, a world leader in technology transfer, has been appointed as chairman of the Intellectual Property (IP) Institute, the UK's leading body in funding research into Intellectual Property Rights (IPR). Ian Harvey succeeds Sir Geoffrey Pattie, who has been involved with the Institute since 1983 when he was a government minister and chairman since the change in structure and name of the Institute in 1994.

The IP Institute is funded by its members who are IPR-dependent companies, legal, accountancy, patent and trade mark firms, the Patent Office, as well as individual professionals and students. Funds for particular projects may also come from the research councils, Government and EU sources. Research covers all areas of IPR with current projects including areas as diverse as the impact of the Internet on copyright and the 'exhaustion of rights' which is concerned with the costs or benefits of grey markets in branded or patented goods.

Ian Harvey said: "I would like to thank Sir Geoffrey for his major contribution in taking the IP Institute forward to its position today. The UK and Europe are heavily dependent on intellectual property for industries and exports such as music and branded goods, as well as its patent-dependent industries such as pharmaceuticals and biotechnology. The IP Institute's role in funding and disseminating research, providing education programmes and defining key legislative issues is growing significantly in a world where IPR is of fundamental importance."

Contact

Andy Burrows

Tel: +44 (0)20 7575 0000

BTG plc

Email: andy.burrows@btgplc.com

Notes to Editors:

The IP Institute

The purpose of the IP Institute is to increase the contribution of IPR to economic well-being by timely, relevant and authoritative research, by informing policy makers and by public debate. IP Institute sponsored research includes the legal, economic and financial aspects of IPR. The Institute is based in London but commissions research from UK and elsewhere.

Major corporate subscribers of the IP Institute are Astra-Zeneca, BBC, BTG, Celltech, EMI, GEC, GlaxoWellcome, Nycomed Amersham, Procter & Gamble and Unilever. Major professional firm subscribers are Allen & Overy, Bird & Bird, Bristows, Clifford Chance, Denton Hall, Frank B. Dehn, Freshfields, Haseltine Lake, Mewburn Ellis, PricewaterhouseCoopers, Simmons & Simmons, Slaughter & May, Stringer Saul and Theodore Goddard.

Ian Harvey

Mr Harvey, aged 54, has an MA in Mechanical Sciences from Cambridge University and an MBA from Harvard University. He was with Vickers and Laporte Industries for ten years followed by seven years at The World Bank. He joined BTG in 1985 as Chief Executive. Between 1988 and 1993 he served as a member of the Prime Minister's Advisory Council on Science and Technology. He is a fellow of Nottingham University and has been a member of the Advisory Panel for SPRU (Science and Technology Policy Research of Sussex University) since 1989. He is a Director of Primaxis Technology

Ventures Inc. based in Canada and a Member of the Appointments Committee of the Particle Physics and Astronomy Research Council. He joined the IPI Board in 1998. He is a companion of the British Institute of Management and sits on the Companions' Board, and a member of Air Products & Chemicals Inc European Advisory Council.

[Back to press releases](#)

At BTG we are focused on developing innovative products in specialist areas of medicine to better serve doctors and patients.

© 2017 BTG International Ltd. All rights reserved. "See More, Reach Further, Treat Smarter", "Imagine where we can go", and BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd in the US, EU and certain other territories. Bead Block, DC Bead, DC Bead LUMI, LC Bead and LC Bead LUMI are trademarks and/or registered trademarks of Biocompatibles UK Ltd. EKOS and EkoSonic are registered trademarks of EKOS Corporation. GALIL is a trademark of Galil Medical Ltd. PneumRx is a registered trademark of PneumRx, Inc. TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. Variithena is a registered trademark of Provensis Ltd. CroFab and DigiFab are registered trademarks of BTG International Inc. Voraxaze is a registered trademark of Protherics Medicines Development Ltd. Lemtrada is a trademark of Genzyme Corporation. Zytiga is a trademark of Johnson & Johnson. Biocompatibles UK Ltd, EKOS Corporation, Galil Medical Ltd, PneumRx, Inc., Protherics Medicines Development Ltd, and Provensis Ltd are all BTG International group companies. Not all products and/or indications are available in all territories. For prescribing information, safety information, and/or product information, go to: bead-block.com | crofab.com | dcbead.com | dcbeadlumi.com | digifab.us | ekoscorp.com | galilmedical.com | lcbead.com | lcbeadlumi.com | lemtrada.com | pneumrx.com | therasphere.com | variithena.com | voraxaze.com | zytiga.com